It was a pleasure to speak with Dr Lynda Grine (Ghent University Hospital, Ghent, Belgium) about her research into the effects of intermittent fasting on psoriasis.
Her presentation entitled ‘Interim results of the MANGO trial: effects of modified intermittent fasting in psoriasis’ was presented at the EADV Spring Symposium, 6-7 May 2021.
- Could you give us a brief overview of the comorbidities, including metabolic syndrome and leaky gut syndrome, associated with psoriasis? (0:05)
- What is the rationale for intermittent fasting in psoriasis patients? (1:19)
- Could you tell us a little about the MANGO trial protocol? (3:21)
- When will the results be available? (4:47)
Disclosures: Dr Lynda Grine has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed as a highlight of EADV Spring 2021 (Virtual).
Share this Video
Related Videos In Psoriasis
Kim Papp, AAD VMX 2021: Secukinumab PURE Study
We were delighted to discuss with Dr Kim Papp (Probity Medical Research, Waterloo, ON, Canada) results from the PURE study (NCT02786186), designed to investigate the long-term safety profile of secukinumab in patients with moderate to severe chronic plaque psoriasis. The abstract ‘Secukinumab helps achieving clear/almost clear skin and improve quality of life in psoriasis over […]
Siew Eng Choon, AAD VMX 2021: Unmet Needs in Generalised Pustular Psoriasis
It was a pleasure to speak with Dr Siew Eng Choon (Monash University, Malaysia) about the current unmet needs in the treatment of generalised pustular psoriasis (GPP). Disclosures: Dr Siew Eng Choon has received honoraria for serving as a consultant, advisory board member, and/or speaker for AbbVie, Boehringer Ingelheim, Janssen, Leo, Eli Lilly, Leo, Novartis, […]
Siew Eng Choon, AAD VMX 2021: Spesolimab in Generalised Pustular Psoriasis
It was a pleasure to speak with Dr Siew Eng Choon (Monash University, Malaysia) about the first RCT trial conducted in generalised pustular psoriasis (GPP). Effisayil 1 (NCT03782792) is a Phase 2 trial investigating the anti-IL-36 receptor antibody, spesolimab. The abstract entitled ‘Design and rationale of Effisayil 1, a Phase II, multicenter, randomized, double-blind, placebo-controlled […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!